Changes in Hong Kong stocks | Sansheng Pharmaceuticals (01530) rose more than 7% to a record high before reaching a 707 heavy license with Pfizer, ASCO data showed impressive performance

The Zhitong Finance App learned that Sansheng Pharmaceutical (01530) rose by more than 7%, reaching a record high of HK$23.75. As of press release, it rose 7.32% to HK$23.45, with a turnover of HK$917 million.

According to the news, Sansheng Pharmaceutical previously announced that it has granted exclusive development, production, and commercialization rights for its self-developed PD-1/VEGF bispecific antibody SSGJ-707 worldwide (excluding mainland China) to global pharmaceutical giant Pfizer. Under the license agreement, Pfizer will pay a non-refundable down payment of $1.25 billion, as well as a milestone payment of up to $4.8 billion and a double-digit percentage share of sales. Huaxi Securities pointed out that it is expected that Pfizer will pay the down payment during the year, boosting Sansheng Pharmaceuticals' pre-tax profit by about 1,175 million US dollars; at the same time, it will receive potential milestone payments in the future.

Furthermore, on June 1, Sansheng Pharmaceutical presented a phase II study of SSGJ-707 single-agent treatment of advanced NSCLC patients at the ASCO conference. As of March 26, 2025, 83 patients received 5, 10, 20, and 30 mg/kg Q3W doses. Among them, patients with squamous cell carcinoma had an ORR of 75%, patients with non-squamous cell carcinoma 64%, PD-L1 TPS ≥ 50% had an ORR of 77%, and TPS 1-49% of patients with TPS 1 to 49%. The overall disease control rate was 97%, and the incidence rate of grade 3 and above TRAE 24.1%